<code id='218EA100BD'></code><style id='218EA100BD'></style>
    • <acronym id='218EA100BD'></acronym>
      <center id='218EA100BD'><center id='218EA100BD'><tfoot id='218EA100BD'></tfoot></center><abbr id='218EA100BD'><dir id='218EA100BD'><tfoot id='218EA100BD'></tfoot><noframes id='218EA100BD'>

    • <optgroup id='218EA100BD'><strike id='218EA100BD'><sup id='218EA100BD'></sup></strike><code id='218EA100BD'></code></optgroup>
        1. <b id='218EA100BD'><label id='218EA100BD'><select id='218EA100BD'><dt id='218EA100BD'><span id='218EA100BD'></span></dt></select></label></b><u id='218EA100BD'></u>
          <i id='218EA100BD'><strike id='218EA100BD'><tt id='218EA100BD'><pre id='218EA100BD'></pre></tt></strike></i>

          Home / entertainment / focus

          focus


          focus

          author:focus    Page View:616

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In